Target intelligence / Profile preview

Influenza Virus Hemagglutinin Protein B Victoria Lineage Antigen (HA)

Target: HA
Molecular classification: Glycoprotein, Viral Surface Protein

Overview

The hemagglutinin (HA) protein of the influenza B virus (Victoria lineage) is a major surface glycoprotein responsible for viral entry into host cells. It mediates receptor binding and membrane fusion, making it a key target for neutralizing antibodies and vaccine development. Ongoing antigenic drift necessitates continuous surveillance and vaccine updates.

Other names: Hemagglutinin B Victoria LineageInfluenza B HA (Victoria)B/Victoria hemagglutinin

Mechanism of action

HA mediates viral entry into host cells by binding to sialic acid receptors and facilitating membrane fusion. Antibodies targeting HA can neutralize the virus by blocking these functions.

Biological functions

Receptor bindingMembrane fusionViral entryAntigen presentationHemagglutination

Disease associations

InfectionInfluenzaRespiratory disease

Safety considerations

Antigenic drift (reduced vaccine efficacy)Potential for escape mutantsImmunogenicity of recombinant HA protein

Interacting drugs

NA inhibitors (e.g., Oseltamivir, Zanamivir) - indirectly affect HA function

1 more in the full profile.

Biomarkers

HA antibody titers (vaccine efficacy)HA sequence variations (antigenic drift)HA expression levels (viral load)

Beyond the preview

Go deeper on Influenza Virus Hemagglutinin Protein B Victoria Lineage Antigen (HA).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Influenza Virus Hemagglutinin Protein B Victoria Lineage Antigen (HA).

Explore the full profile